Volume 15, Issue 2, Pages (March 2012)

Slides:

Advertisements

Similar presentations

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)— Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication.

Advertisements

A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence Susan Ross, MD, FRCPC, Ebony Samuels, PhD, Kerry Gairy, MSc, Sheikh Iqbal, MD,

Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical.

Cost-Effectiveness of Sensor-Augmented Pump Therapy in Adults with Type 1 Diabetes in the United States Shital Kamble, PhD, Kevin A. Schulman, MD, Shelby.

Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis Beth Woods,

Volume 14, Issue 8, Pages (December 2011)

Volume 18, Issue 6, Pages (September 2015)

Volume 16, Issue 6, Pages (September 2013)

Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual.

Volume 15, Issue 8, Pages (December 2012)

Volume 18, Issue 4, Pages (June 2015)

Volume 18, Issue 5, Pages (July 2015)

Volume 18, Issue 2, Pages (March 2015)

Mapping the COPD Assessment Test onto EQ-5D

Volume 15, Issue 2, Pages (March 2012)

Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results Becky Pennington, MSc,

Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-

Individualized Positron Emission Tomography–Based Isotoxic Accelerated Radiation Therapy Is Cost-Effective Compared With Conventional Radiation Therapy:

Volume 17, Issue 2, Pages (March 2014)

Volume 14, Issue 1, Pages (January 2011)

Volume 15, Issue 1, Pages S20-S28 (January 2012)

Volume 14, Issue 4, Pages (June 2011)

Volume 17, Issue 8, Pages (December 2014)

Volume 18, Issue 8, Pages (December 2015)

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Volume 17, Issue 8, Pages (December 2014)

Volume 14, Issue 4, Pages (June 2011)

Volume 15, Issue 2, Pages (March 2012)

Volume 14, Issue 8, Pages (December 2011)

Multidomain Patient-Reported Outcomes of Irritable Bowel Syndrome: Exploring Person-Centered Perspectives to Better Understand Symptom Severity Scores

Volume 15, Issue 1, Pages (January 2012)

Volume 19, Issue 5, Pages (July 2016)

Volume 17, Issue 2, Pages (March 2014)

Examining the Value of Menopausal Symptom Relief Among US Women

Volume 17, Issue 2, Pages (March 2014)

The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options Axel.

Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico Kely Rely, Rosa María.

Value in Health Regional Issues

Value in Health Regional Issues

Value in Health Regional Issues

Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation.

Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future? Emmanuel Ankrah Odame, MBCHB, MPH Value in.

Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost- Effectiveness Affordability Curves in Health Care Decision Making

Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil Ronaldo K.

Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico Kely Rely, Rosa María.

Value in Health Regional Issues

Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,

Value in Health Regional Issues

Value in Health Regional Issues

Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore Vivianne Shih, PharmD, BCOP, BCPS, Alexandre Chan, PharmD,

Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation.

Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia

Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD

Value in Health Regional Issues

Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project Kyriakos Souliotis, PhD,

Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective Bruno Salgado Riveros,

Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes Maxwell O. Adibe,

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan Yoshie Onishi, MS,

Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD

Value in Health Regional Issues

Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea Ji Haeng Heo, MS, Karen L.

Dossier System as a Practical Tool for Compiling Reimbursement Lists

Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.

Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico

Social Cost of Substance Abuse in Russia

Anut Sakulsupsiri, MSc, Phantipa Sakthong, PhD, Win Winit-Watjana, PhD

Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.

Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov.

Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD

Presentation transcript:

Volume 15, Issue 2, Pages 231-239 (March 2012) Cost-Effectiveness Evaluation in Sweden of Escitalopram Compared with Venlafaxine Extended-Release as First-Line Treatment in Major Depressive Disorder Göran Nordström, PhD, Natalya Danchenko, PhD, Nicolas Despiegel, MSc, Florence Marteau, MSc Value in Health Volume 15, Issue 2, Pages 231-239 (March 2012) DOI: 10.1016/j.jval.2011.09.011 Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Cost-effectiveness model of escitalopram or venlafaxine extended-release for major depressive disorder in Sweden: 1) The venlafaxine arm is a clone of the escitalopram arm (implying the same structure). 2) Sustained remission at 6 mo: patients who achieved remission at week 8 since treatment initiation and remaining in remission by week 24. Patients were expected to continue on the same medication for another 4 mo (maintenance therapy). 3) Relapse at 6 mo: Patients who achieved remission at week 8 since treatment initiation but subsequently relapsed. 4) Premature stop at 8 wk: Patients who did not achieve remission during the first 8 wk of therapy and stopped medication. 5) Switch at 8 wk: Patients who did not achieve remission during the first 8 wk of therapy and switched to another medication. 6) The model was developed by using Data 4.0 software (TreeAge Software, Inc., Williamstown, MA). AD, antidepressant drug; Esc, escitalopram; MDD, major depressive disorder. Value in Health 2012 15, 231-239DOI: (10.1016/j.jval.2011.09.011) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 The cost-effectiveness of escitalopram compared with venlafaxine extended-release: incremental QALYs versus incremental total cost, base analysis. QALYs, quality-adjusted life-years. Value in Health 2012 15, 231-239DOI: (10.1016/j.jval.2011.09.011) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 3 Cost-effectiveness acceptability curve for base scenario, and conservative scenario analysis. QALY, quality-adjusted life-year. Value in Health 2012 15, 231-239DOI: (10.1016/j.jval.2011.09.011) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions